北京若生智能科技有限公司
Drug Database
AN

antithrombin III

✓ Approved

GC Biopharma · SERPINC1 · 细胞治疗

什么是 antithrombin III？

antithrombin III 是一种细胞治疗，由GC Biopharma研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intravenous (IV)。

药物档案

公司GC Biopharma
药物类别细胞治疗
分子靶点SERPINC1
给药途径Injectable (Others), Intravenous (IV)
状态Approved
来源： ClinicalTrials.gov, GC Biopharma

作用机制

分子靶点

antithrombin III 作用于 1 个分子靶点：

SERPINC1serpin family C member 1 (ATIII, AT3D)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

antithrombin III 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Congenital, familial and genetic disordersAntithrombin III deficiency✓ Approved

相关研究文献

PubMedJournal of medical case reports2026-10-27

Concurrent acute pancreatitis and splanchnic vein thrombosis in a heavy smoker: a dynamic D-dimer-based diagnostic algorithm and mechanistic insights-a case report.

Liu Ligang L, Li Fenqiang F, Liu Tingting T, Hu Zhengtao Z et al.

Splanchnic vein thrombosis (SVT) concurrent with acute pancreatitis (AP) at initial diagnosis is rare and its pathophysiology remains unclear. We describe a heavy smoker who presented with AP with occult non-occlusive SVT, which paradoxically progressed to complete thrombotic occlusion. A 52-year-old male heavy smoker (40-60 cigarettes/day for 30 years) presented with epigastric pain and was diagnosed with AP after excluding common etiologies. On admission, D-dimer was markedly elevated at 9.15 mg/L (18 times the upper limit of normal). By day 12, despite radiological resolution of pancreatic inflammation and a significant c-reactive protein (CRP) reduction (139.16 to 45.35 mg/L), he developed mesenteric ischemia. Laboratory findings revealed a paradoxical "dynamic decoupling": D-dimer further escalated to 9.52 mg/L, fibrinogen (FIB) was consumed to 2.72 g/L, and antithrombin III (AT-III) was critically depleted to 45%. Contrast-enhanced CT confirmed complete thrombotic occlusion of the superior mesenteric, splenic, and portal veins; retrospective review verified non-occlusive SVT at onset. Standard systemic anticoagulation failed to halt thrombotic progression, reaching a "pharmacological ceiling" due to profound AT-III depletion. Transjugular endovascular intervention (thrombus aspiration and catheter-directed thrombolysis) successfully reversed the intestinal ischemia. In heavy smokers with AP, an initial D-dimer exceeding 18 times the upper limit of normal should prompt early contrast-enhanced CT to exclude occult SVT. When standard systemic anticoagulation fails due to a "pharmacological ceiling" of depleted antithrombin, timely endovascular escalation is a key salvage strategy.

PMID 42934804
阅读全文 →
PubMedAntibiotics (Basel, Switzerland)2026-10-27

Antimicrobial Activity of Lipophilic Gallium-Based Compounds: An Emerging Frontier in Metal-Based Antimicrobials.

Abeydeera Nalin N, Pant Bishnu B, Chen Guanyu G

Antimicrobial resistance (AMR) is an increasing global health threat that underscores the urgent need for antimicrobial agents with mechanisms of action distinct from those of conventional antibiotics. Gallium (Ga) has emerged as a promising metal-based antimicrobial owing to the chemical similarity of Ga(III) to Fe(III), which enables it to interfere with bacterial iron acquisition and utilization. In contrast to Fe(III), Ga(III) is redox-inactive under physiological conditions and cannot support the redox reactions required for many iron-dependent cellular processes, thereby disrupting bacterial metabolism. This review highlights recent advances in gallium-based antimicrobial strategies, with particular emphasis on the role of ligand coordination in modulating the antibacterial activity of Ga(III) against drug-resistant pathogens. Emerging evidence indicates that coordination with lipophilic ligands can enhance the cellular update and accumulation of Ga(III) and may confer additional antibacterial effects beyond Fe(III) mimicry alone. These findings suggest that ligand design is a key strategy for tuning the physicochemical properties and antimicrobial activity of gallium complexes. Rational development of ligand-coordinated Ga(III) complexes may therefore provide new therapeutic approaches for combating multidrug-resistant bacterial infections.

PMID 42938716
阅读全文 →
PubMedMolecules (Basel, Switzerland)2026-10-27

Antimony(III) and Bismuth(III) Halide Complexes Containing Thiazole-and Thiadiazole-Based Mercapto Ligands: Synthesis, Structural Characterization, and Biological Activity.

Ozturk Ibrahim I II, Albayrak Cemile C, Grześkiewicz Anita M AM, Kubicki Maciej M et al.

Sulfur-rich heterocyclic ligands are widely employed as building blocks for biologically active main-group metal complexes owing to their versatile coordination behavior. In this study, four new antimony(III) and bismuth(III) halide complexes based on 2-mercapto-4-methylthiazole and 2-mercapto-5-methyl-1,3,4-thiadiazole ligands were synthesized, spectroscopically characterized, and evaluated for their biological activity. The crystal structures of complexes 1, 3, and 4 were determined by single-crystal X-ray diffraction, revealing distorted square-pyramidal coordination geometries with the ligands coordinated in their neutral thione form through the sulfur donor atom. Single-crystal X-ray diffraction analyses reveal distinct solid-state arrangements: complex 1 is monomeric, complex 3 forms a chloride-bridged polymer, and complex 4 forms bromide-bridged dimers. Time-dependent molar conductivity and UV-Vis measurements showed no substantial changes under the investigated conditions. The antimony(III) complexes exhibited antiproliferative activity against HeLa cells, whereas the bismuth(III) analogues were inactive within the investigated concentration range. The complexes also showed modest antibacterial effects in the disc-diffusion screening assay, with the most pronounced inhibition-zone responses observed against E. coli. Overall, the biological results reveal differences in activity among the investigated Sb(III) and Bi(III) complexes under the tested conditions.

PMID 42943851
阅读全文 →
PubMedFrontiers in neurology2026-10-27

Functional divergence of the synapsin family in glioblastoma: Synapsin III as a candidate differentiation-restoring node.

Dai Xiangyu X, Ji Yujie Y, Cai Zheng Z, Zeng Haixin H et al.

Glioblastoma (GBM) remains an aggressive adult primary brain tumor despite surgery, radiotherapy and temozolomide-based chemotherapy, partly because glioblastoma stem cells (GSCs) retain self-renewal capacity, lineage plasticity and therapeutic resistance. Cancer neuroscience has shown that glioma cells receive activity-dependent neuronal signals and exploit neural circuits to support tumor growth and invasion. Synaptic proteins may therefore regulate both neuron-glioma communication and tumor-cell state. Synapsin I, II, and III share conserved N-terminal domains but differ in C-terminal architecture, developmental expression and physiological function. An emerging model of functional divergence in GBM is supported by a recent preclinical study comparing Synapsin III with Synapsin I and II. In the tested GSC models, increasing Synapsin III promoted a neuronal-like differentiated phenotype through a neuregulin 3 (NRG3)-JAG1-NOTCH1 mechanism, with reduced stemness and proliferative growth. This review integrates structural, physiological and GBM-focused evidence to examine how the developmental functions of Synapsin III may be repurposed in malignant stem-like cells. Independent replication, durable loss of tumorigenicity and tumor-selective delivery are priorities for translation. Synapsin III is a candidate differentiation-restoring node whose clinical relevance remains to be established.

PMID 42936488
阅读全文 →
PubMedJournal of the American Chemical Society2026-10-27

A Nonheme μ-1,2-Peroxo Dicobalt(III) Complex Acting as a Key Intermediate for Selective Two-Electron/Two-Proton Catalytic Reduction of Dioxygen to Hydrogen Peroxide.

Kumar Akhilesh A, Manoj Alka A, Seo Mi Sook MS, Kang Vom V et al.

The two-electron/two-proton reduction of O2 to H2O2 has attracted considerable attention recently, as H2O2 is both a valuable oxidant and a potential fuel for H2O2 fuel cells. While metalloporphyrins have been extensively studied as efficient catalysts for this reaction, nonheme metal complexes remain largely underexplored and key catalytic intermediates and rate-determining steps have rarely been identified. Herein, we report the isolation, along with the structural and spectroscopic characterization, of a nonheme μ-1,2-peroxo dicobalt(III) complex, [Co2(μ-1,2-O2)(L)2]2+ (HL = 2-[benzyl[bis(pyridin-2-yl)methyl]amino]-N-(quinolin-8-yl)acetamide), which serves as a key intermediate in the selective two-electron/two-proton catalytic reduction of O2. In the presence of trifluoroacetic acid in acetonitrile at 298 K, ferrocene derivatives act as electron donors to produce H2O2 with 100(2)% selectivity; the generated H2O2 is stable for up to 3 h under the catalytic conditions. The catalytic cycle has been elucidated through an analysis of both overall kinetics and the kinetics of individual steps. The rate-determining step in the catalytic cycle is the electron transfer from 1,1'-dimethylferrocene (Me2Fc) to the mononuclear Co(III) complex, [CoIII(L)]2+, generating 1,1'-dimethylferrocenium ion (Me2Fc+) and [CoII(L)]+. The resulting Co(II) species reacts with O2 to form [CoIII2(μ-1,2-O2)(L)2]2+, which upon protonation yields H2O2 and regenerates two equivalents of [CoIII(L)]2+. This study establishes a new catalytic pathway via the μ-1,2-peroxo dicobalt(III) complex for the selective reduction of O2 to H2O2 using a nonheme metal complex with perfect selectivity. Furthermore, the one-electron oxidation of the μ-1,2-peroxo dicobalt(III) complex affords the corresponding μ-1,2-superoxo dicobalt(III) complex, which was characterized by EPR, CSI-MS, and resonance Raman spectroscopies.

PMID 42938009
阅读全文 →
PubMedMetabolites2026-10-27

Metabolic and Synthetic Dysfunction in Acute Fatty Liver of Pregnancy: Reappraising the Swansea Criteria-A Narrative Review.

Solomon Condriuc Iustina Petra IP, Popovici Razvan R, Cosovanu Eric Oliviu EO, Mogos Raluca Anamaria RA et al.

Acute fatty liver of pregnancy (AFLP) is a rare microvesicular steatotic liver disease of late gestation, linked to impaired mitochondrial fatty acid β-oxidation, in which management centres on recognition and delivery before overt hepatic and multiorgan failure has developed. The Swansea criteria, which require six or more of fourteen features in the absence of an alternative explanation, define AFLP in guidelines and in most published cohorts. This narrative review examines how the criteria behave across the course of the illness and which markers might signal the disease earlier. The criteria are frequently fulfilled once AFLP is clinically established, but their accuracy against an independent reference standard derives from one small, high-prevalence biopsy series, and their specificity against haemolysis, elevated liver enzymes and low platelets (HELLP) syndrome and other causes of acute liver failure appears limited. Because several criteria index established organ failure, the threshold may remain unmet earlier in the illness, a hypothesis consistent with limited retrospective evidence; to our knowledge, no study has evaluated the criteria prospectively at initial presentation. We relate each criterion to hepatic energy failure and appraise candidate early markers, including coagulation indices, antithrombin, conjugated hyperbilirubinaemia, hypocholesterolaemia, soluble fms-like tyrosine kinase-1 and metabolite-level signals of fatty acid oxidation failure; none has a validated early diagnostic threshold. We outline a conceptual, hypothesis-generating framework for prospective research that would complement, not replace, the Swansea case definition.

PMID 42941274
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多antithrombin III